Asia Spotlight: Merck In Multiple Partnerships To Finance Hep C Treatment In India
Executive Summary
Merck’s Indian arm MSD India has linked up with a financial institution and is considering national rollout of a funding plan that aims to stretch the cost of hepatitis C treatment over several months. The impact could mean that up to about 45% of the affected population might get treatment, up from 3% now.